May 12, 2021 -- Nuclera has acquired E Ink's microfluidics unit, and, together, they have developed a desktop bioprinter that will be commercially available in 2022.
The microfluidics unit will be part of the newly formed U.S. subsidiary of Nuclera. Under the deal, E Ink will contribute intellectual property, equipment, and assistance from scientists and engineers and will be made the largest stakeholder in Nuclera.
Nuclera's desktop bioprinter, which is powered by microfluidic technology. Image courtesy of Nuclera.
The companies have been working together to create a bioprinter since 2018. E Ink's digital microfluidics has been combined with Nuclera's biopolymer synthesis technology to create lab-on-chip technology that allows users to digitally program bioprinting of proteins and genes on a desktop for next-day production.
The company expects to commercialize the product in 2022.
Copyright © 2021 scienceboard.net